Efficacy of Propranolol for the treatment of central nervous system hemangioblastomas in von Hippel-Lindau disease: a randomized controlled clinical trial

Efficacy of Propranolol for the treatment of central nervous system hemangioblastomas in von Hippel-Lindau disease: a randomized controlled clinical trial - PRO-HEB

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2022-001174-54-FR

Enrollment

Registered

2022-04-05

Start date

2022-05-19

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

von Hippel-Lindau desease

Interventions

Trade Name: PROPRANOLOL 40 mg, comprimé sécable Product Name: PROPRANOLOL Pharmaceutical Form: Tablet INN or Proposed INN: Propranolol CAS Number: 525-66-6 Concentration unit: mg milligram(s) Concent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ND Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 40

Exclusion criteria

Exclusion criteria: ND

Design outcomes

Primary

Measure	Time frame
Main Objective: ND;Secondary Objective: ND;Primary end point(s): ND;Timepoint(s) of evaluation of this end point: ND	—

Secondary

Measure	Time frame
Secondary end point(s): ND;Timepoint(s) of evaluation of this end point: ND	—

Countries

France

Contacts

Public ContactYAHMI MALIKA

Assistance Publique – Hôpitaux de Paris (AP-HP)

malika.yahmi@aphp.fr330144 84 17 45

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026